Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19

Frank L. van de Veerdonk,Ilse J.E. Kouijzer,Aline H. de Nooijer,Hans van der Hoeven,Coen Maas,Mihai G. Netea,Roger J. M. Brüggemann

Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19

2020

Frank L. van de Veerdonk
Ilse J.E. Kouijzer
Aline H. de Nooijer
Hans van der Hoeven
Coen Maas
Mihai G. Netea
Roger J. M. Brüggemann

This case-control study examines the association between receipt of the bradykinin 2 (B2) receptor antagonist icatibant and improved oxygenation in patients with coronavirus disease 2019 (COVID-19).

Keywords:

Pharmacology
Bradykinin
Icatibant
b2 receptor
Kinin
Antagonist
Medicine
severe acute respiratory syndrome coronavirus 2
2019 20 coronavirus outbreak
Coronavirus disease 2019

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations